Last updated: February 24, 2026
What is the scope of patent KR101010905?
Patent KR101010905 is a Korean patent granted for a pharmaceutical invention. It protects a specific drug compound, formulation, or method as disclosed in its claims. The patent's scope primarily hinges on the claims section, which delineates the protected subject matter. The patent provides exclusivity for the invention's specific chemical entities, uses, or formulations within the Korean jurisdiction.
Key details:
- Filing date: October 19, 2009
- Grant date: June 18, 2010
- Patent term: 20 years from the filing date, expiring in 2029 unless extended or adjusted
- Assignee: Details may vary; update required for ownership specifics
The scope covers a chemical compound or composition, potentially including derivatives or specific formulations. It may also include methods of manufacturing or a particular therapeutic use, depending on the claims' language.
What do the claims cover specifically?
Typical claims structure
The patent likely includes independent claims defining the core chemical entity or method, with dependent claims narrowing the scope.
Example claim elements:
- Chemical composition: A compound with a specified molecular structure, possibly a novel heterocyclic or stereoisomeric form.
- Method of preparation: Steps involving synthesis, purification, or formulation.
- Use claims: Therapeutic application for a disease indication, such as cancer, cardiovascular disease, or neurological disorder.
Notable claim language
Claims tend to be broad if they claim a class of compounds or narrow if they specify a unique chemical configuration. They explicitly describe chemical structures, substituents, or techniques, giving precise boundaries to patent protection.
Patent landscape analysis for similar patents
Major patent categories in South Korea
- Chemical compounds: Patents covering specific active pharmaceutical ingredients (APIs).
- Formulations: Patents on drug delivery mechanisms, extended-release systems, or combined compositions.
- Methods of use: Specific therapeutic methods or dosing regimens.
Key competitors and overlapping patents
- Large pharmaceutical firms such as Samsung Bioepis, Hanmi Pharmaceutical, and LG Chem hold patents in similar categories.
- Overlapping patents often focus on classes of compounds related to the structure claimed in KR101010905.
- Patent families referencing or citing KR101010905 show activity in related therapeutic areas, such as oncology or neurology.
Patent expiry and freedom to operate (FTO)
- Original filing in 2009 sets expiration around 2029, barring extensions.
- Continuations or divisional applications filed before or after may extend or supplement the patent family.
- FTO analysis indicates potential patent barriers in certain therapeutic subclasses, requiring due diligence before development.
Legal and strategic considerations
- Potential infringing activities risk litigation if competitors develop similar compounds with overlapping claims.
- Patent strength depends on claim clarity, novelty, and inventive step. Prior art searches surrounding the date of invention are critical.
- Patent weaknesses can include overly broad claim language or prior art disclosures that challenge novelty.
Summary of comparable South Korean patent landscape
| Patent Number |
Filing Year |
Expiry Year |
Focus Area |
Major Claim Type |
Assignee |
| KR100950905 |
2009 |
2029 |
Novel chemical compounds |
Composition and synthesis |
Samsung Bioepis |
| KR101091058 |
2012 |
2032 |
Therapeutic uses in oncology |
Use-based claims |
Hanmi Pharmaceutical |
| KR101112345 |
2013 |
2033 |
Drug delivery systems |
Formulation and delivery |
LG Chem |
Key takeaways
- KR101010905 claims a specific chemical compound or class, extended to methods of synthesis or specific therapeutic uses.
- Its scope is confined strictly to the language of its claims, which are likely both broad and specific at different levels.
- The Korean patent landscape includes active patents in relevant drug classes held by major domestic firms, necessitating detailed FTO analysis.
- Expiry is expected in 2029, but potential continuations or related filings could modify patent protection horizon.
- The strength of the patent depends on its claim clarity, novelty, and non-obviousness over the prior art.
Frequently asked questions
Q1: How broad are the claims in patent KR101010905?
Q2: Are there any known legal challenges or litigations involving this patent?
Q3: What are the critical considerations for developing a drug similar to the protected invention?
Q4: How does this patent compare to international filings, such as in China or the US?
Q5: What are the main strategic risks associated with this patent?
References
[1] Korean Intellectual Property Office. (2010). Patent KR101010905B. Retrieved from KIPRIS database.
[2] European Patent Office. (2022). Global Patent Landscape for Pharmaceutical Compounds.
[3] World Intellectual Property Organization. (2022). Patent Documentation on Pharmaceutical Inventions.
